课题基金 / 基金详情

The Early Detection Research Network Biomarker Resource Laboratory at UCLA

The Early Detection Research Network Biomarker Resource Laboratory at UCLA
加州大学洛杉矶分校早期检测研究网络生物标志物资源实验室
批准号:
8296107
负责人:
DAVID S. CHIA
金额:
$37.91万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-16 至 2015-06-30

项目摘要

项目成果

DAVID S. CHIA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):加州大学洛杉矶分校生物标志物参考实验室(UCLA BRL)旨在成为edrn资助的加州大学洛杉矶分校生物标志物参考实验室的延续和扩展。值得注意的是,UCLA BRL已经非常成功地建立了许多EDRN合作,并为EDRN研究人员构建并成功利用了组织微阵列资源。我们的目标与EDRN的使命紧密一致,包括:i)利用我们多样化和广泛的基础设施和高技能人才来测试、评估、量化、验证和优化对早期肿瘤标志物有用的生物标志物的检测。为此,我们建立了科学中心,可以测试组织和/或液体中的生物标志物,这些生物标志物是蛋白质和/或核酸。为此,科学中心在组织(全组织切片或“智能高密度组织微阵列”)、蛋白质(包括常规和高通量蛋白质)和核酸(包括表达谱、DNA修饰或突变、染色体异常和/或microRNA谱)的分析性能和开发方面拥有丰富的经验和专业知识。ii)这包括一个发展项目,专注于利用高密度组织微阵列结合一种新的数据挖掘工具套件来定义临床有用的肿瘤标志物;iii)继续在加州大学洛杉矶分校进行一个高度专业和专注的项目,但同时又灵活和具有成本效益,以应对不断发展的EDRN项目的挑战;iv)对协作,团队合作的坚定承诺;与EDRN成员共享资源和数据,以促进确定临床有用的肿瘤生物标志物的目标。加州大学洛杉矶分校BRL的领导层非常有能力和热情,并坚定地致力于EDRN的目标。此外,UCLA- brl还得到了来自医学院、Jonsson综合癌症中心、UCLA肺癌项目和UCLA前列腺癌孢子的强有力的机构支持。
英文摘要
DESCRIPTION (provided by applicant): The UCLA Biomarker Reference Laboratory (UCLA BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA BRL. Significantly, the UCLA BRL has been highly successful having established numerous EDRN collaborations and constructed and successfully utilized tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) the utilization of our diverse and extensive infrastructure and highly skilled personnel to test, evaluate, quantify, validate and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers which are protein and/or nucleic acid in nature in tissue and/or in fluids. To this end, the Scientific Centers have extensive experience and expertise in assay performance and development for tissues (full tissue sections or 'intelligent high-density tissue microarrays), proteins (including conventional and high-throughput protemics), and nucleic acids (including expression profiles, DNA modifications or mutations, chromosomal abnormalities, and/or microRNA profiles), ii) This includes a developmental program focused on defining clinically useful tumor markers utilizing high density tissue microarray combined with a novel data-mining tool suite, iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program, iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful tumor biomarkers. The UCLA BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer Program, and the UCLA Prostate Cancer SPORE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients
BIOMARKERS VALIDATION LABORATORIES
BIOMARKERS VALIDATION LABORATORIES
海外基金